Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Liver Cancer Risk Assessments: New Tool Beats Standard Screening
Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa
Ovarian Cancer Survival Varies Widely Among Asian American Subgroups
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
Liver Steatosis, Fibrosis Highly Prevalent in People Living With HIV
Possible Genetic Links Between Hidradenitis Suppurativa and CAD, Diabetes Risks